Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Presentation (November 2015)
27 slides from Diasorin's investor presentation, November 2015
Slide 1: Company Presentation
Company Presentation
Slide 2: Company Profile
COMPANY PROFILE Global Leader in IVD for over 40 years Italian Worldwide Broadest Menu multinational company in CLIA immunoassay Listed on the stock Focus on Specialty market in the FTSE Mid Products Cap Index New Player in Molecular Diagnostics 2
Slide 3: History
HISTORY Agreement with Quest Laboratories for Vitamin D 2015 Agreement with Beckman Coulter for the commercialization of Hepatitis and HIV in China Consolidation and new perspective The expansion of CLIA menu continues at the rate of 6-8 new 2014 products each year, as does the success and growth of
Slide 4: Shareholders’ structure
Shareholders’ structure Carlo Rosa 8.540% Market Chen Menachem Even 39.990% 4.466% Finde ss 43.957% Threadneedle Asset Management Holdings Ltd. 3.047% *as of 1 October 2015 4
Slide 5: Global Presence
GLOBAL PRESENCE subsidiaries Germany - Dietzenbach* ireland - dublin* • TUMOR MARKERS distributors • MOLECULAR • HORMONOLOGY * R&D facility * R&D facility usa - stillwater* uk - dartford • BONE & MINERAL • MUREX ELISA • ENDOCRINOLOGY * R&D facility Italy - saluggia, Gerenzano* • INFECTIOUS DISEASE *
Slide 6: Systems & Solutions
Systems & Solutions
Slide 7: Systems & Solutions
SYSTEMS & SOLUTIONS Immunodiagnostics Molecular Diagnostics EXTRACTION CLIA ChemiLuminescent Immuno Assay: latest and most used technology by hospitals and private laboratories, with tests run on random access and fully automatized systems, providing results in 30-45 minutes 1st phase: Extraction of
Slide 8: Focus on LIAISON XL
FOCUS ON LIAISON ® XL Fully automated solution Samples identified via a bar code reader and reported to user Complete sample processing, measurement Flexible configuration and evaluation Perfect compatibility of tests with LIAISON analyzer High efficiency Quality of all samples monitored High Throug
Slide 9: Focus on Laboratory Automation System
FOCUS ON LABORATORY AUTOMATION SYSTEM Streamline the process and improve the efficency of your laboratory LIAISON® XLine connects multiple LIAISON® XL to Pre-Analytical modules offering the complete automation of the working process and a wide range of Immunology assays available. Easy to navigate,
Slide 10: Installed Base Evolution
INSTALLED BASE EVOLUTION 5,272 5,872 4,740 + 1 6.1% R CAG 4,206 1,665 1,075 3,641 605 128 2,975 2,510 2,070 4,078 4,135 4,197 4,207 3,641 2,975 2,510 2,070 2007 2008 2009 2010 2011 2012 2013 2014 LIAISON® LIAISON® XL TOTAL 10
Slide 11: DiaSorin Supply Chain
DIASORIN SUPPLY CHAIN 1 2 2 3 raw materials production production distribution Biology & Biochemical Biology & Biochemical transportation by air, sea or land of reagents to logistic hubs or clients Department Department buy make Biological and chemical production and storage Manufacturing storage A
Slide 12: Products
Products
Slide 13: The LIAISON Family Collection
THE LIAISON FAMILY COLLECTION 107 Assays Menu and leading position in Specialty Assays BONE & MINERAL AUTOIMMUNITY DIABETES TORCH CHLAMYDIA 25-OH Vitamin D TOTAL ANA Screen C-Peptide Toxo IgG Chlamydia t. igg N-TACT® PTH Gen II dsDNA Insulin Toxo IgM Chlamydia t. iga 1-84 PTH tTG IgA Toxo IgG Avidit
Slide 14: Strategy
Strategy
Slide 15: Hepatitis and Retroviruses
Hepatitis and Retroviruses
Slide 16: Hepatitis & Retroviruses
HEPATITIS & RETROVIRUSES Diasorin experience and reputation in Infectious Diseases Diasorin full menu availability HIV HIV HT HBsAg Chagas Leverage on T. pallidum HTLV I-II HCV Liaison® XL 16
Slide 17: Gastro-intestinal stool testing
Gastro-intestinal stool testing
Slide 18: New Automated System in Stool Testing
NEW AUTOMATED SYSTEM IN STOOL TESTING set up of optimal assay conditions with liaison® and liaison® xl Gastro-intestinal Infections + companion one-step simple sample preparation device C. Difficile Toxins A&B Enterohemorragic E. Coli C. Difficile GDH Rotavirus H. Pylori Adenovirus Gastro-intestinal
Slide 19: Endocrinology & Hypertension
Endocrinology & Hypertension
Slide 20: Endocrinology & Hypertension
ENDOCRINOLOGY & HYPERTENSION Chronic Kidney Disease (CKD) and Bone Metabolism ckd bone mass loss High bone turnover Low bone turnover (increased reabsorption) (reduced formation) Hyperphosphate FGF-23 Hyperphosphate FGF-23 Reduced 1.25 Vit D 1.25 Vit D Reduced 1.25 Vit D 1.25 Vit D In Development Hi
Slide 21: Molecular Diagnostics
Molecular Diagnostics
Slide 22: DiaSorin in the Molecular Diagnostics
DIASORIN IN THE MOLECULAR DIAGNOSTICS 3 phases to run STRATEGY a molecular diagnostic test Reagent + + kits Sample preparation phase: Extraction technology dna/rna amplification: Amplification + Detection on the same machine: Amplification technology LAMP technology on the LIAISON IAM 7 specialty as
Slide 23: Research & Development
RESEARCH & DEVELOPMENT eT
Slide 24: R&D: Main Competencies & Facts
R&D: MAIN COMPETENCIES & FACTS Molecular Diagnostics •New Reagents ImmunoDiagnostics •New Technologies • New Assays Prototypes •Assays Optimization • New Technologies •Pre-industrialization • New Reagents • Assays Optimization • Pre-industrialization Molecular Diagnostics •New Reagents ImmunoDiagnos
Slide 25: Immunodiagnostics Pipeline 2012-2015
IMMUNODIAGNOSTICS PIPELINE 2012-2015 Infectious Diseases Specialty ID Serology Blood Banks Automated Stool Testing Mumps IgG, IgM HTLV I II Clostridium difficile Toxin A/B Calprotectin Measles IgG, IgM Chagas Clostridium difficile GDH Campylobacter Chlamydia Trachomatis IgG, IgA HIV Combo High Throu
Slide 26: Molecular Diagnostics Pipeline 2012-2015
MOLECULAR DIAGNOSTICS PIPELINE 2012-2015 Infectious Diseases Parvovirus (PARVO) Varicella Zoster Virus (VZV) Cytomegalovirus (CMV) BK Virus (BKV) Toxoplasmosis (TOXO) Herpes Simplex Virus (HSV 1&2) Onco-Hematology Chronic Myeloid Leukemia (CML) Acute Lymphoblastic Leukemia (ALL) Acute Promyelocitic
Slide 27: The Diagnostic Specialist
The Diagnostic Specialist